... Faspro Formulation for Multiple Myeloma — Clinical Oncology News Exploring Behaviors, Treatment Beliefs, and Barriers to Oral Chemotherapy Adherence Among Adult Leukemia Patients in a Rural Outpatient Setting — BMC Research Notes Oral Therapies in Myeloma: Medication Adherence — Leukemia & Lymphoma Society Determinants of Satisfactory Patient Communication ...
7 Ways To Avoid Stopping Treatment for Multiple Myeloma
... Faspro Formulation for Multiple Myeloma — Clinical Oncology News Exploring Behaviors, Treatment Beliefs, and Barriers to Oral Chemotherapy Adherence Among Adult Leukemia Patients in a Rural Outpatient Setting — BMC Research Notes Oral Therapies in Myeloma: Medication Adherence — Leukemia & Lymphoma Society Determinants of Satisfactory Patient Communication ...
... Highlights of Prescribing Information: Darzalex (Daratumumab) Injection, for Intravenous Use — Janssen Pharmaceutical Companies Spinal Disease in Myeloma: Cohort Analysis at a Specialist Spinal Surgery Centre Indicates Benefit of Early Surgical Augmentation or Bracing — BMC Cancer Management of Pathological Thoracolumbar Vertebral Fractures in Patients ...
Back Pain and Myeloma: What It Feels Like
... Highlights of Prescribing Information: Darzalex (Daratumumab) Injection, for Intravenous Use — Janssen Pharmaceutical Companies Spinal Disease in Myeloma: Cohort Analysis at a Specialist Spinal Surgery Centre Indicates Benefit of Early Surgical Augmentation or Bracing — BMC Cancer Management of Pathological Thoracolumbar Vertebral Fractures in Patients ...
... Food and Drug Administration FDA Drug Approval: Elotuzumab in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma — Clinical Cancer Research Empliciti (Elotuzumab) for Injection, for Intravenous Use — Bristol-Myers Squibb Darzalex (Daratumumab) — International Myeloma Foundation Sarclisa (Isatuximab-Irfc ...
8 Refractory Myeloma Therapies: Know Your Treatment Options
... Food and Drug Administration FDA Drug Approval: Elotuzumab in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma — Clinical Cancer Research Empliciti (Elotuzumab) for Injection, for Intravenous Use — Bristol-Myers Squibb Darzalex (Daratumumab) — International Myeloma Foundation Sarclisa (Isatuximab-Irfc ...
... These include daratumumab (Darzalex), daratumumab and hyaluronidase-fihj (Darzalex Faspro), and isatuximab-irfc (Sarclisa). Another monoclonal antibody, elotuzumab (Empliciti), attaches to a myeloma cell protein called SLAMF7. The myeloma drug belantamab mafodotin-blmf (Blenrep) works differently. ...
Chemotherapy for Multiple Myeloma: Your Guide
... These include daratumumab (Darzalex), daratumumab and hyaluronidase-fihj (Darzalex Faspro), and isatuximab-irfc (Sarclisa). Another monoclonal antibody, elotuzumab (Empliciti), attaches to a myeloma cell protein called SLAMF7. The myeloma drug belantamab mafodotin-blmf (Blenrep) works differently. ...
... Researchers have also developed a newer version of this drug called daratumumab hyaluronidase-fihj (Darzalex Faspro). Although daratumumab is typically given intravenously (through an IV infusion), daratumumab hyaluronidase-fihj treatments are simply injected under the skin (subcutaneously) and thus administered much faster. The U.S. ...
New Treatment Options for Relapsed or Refractory Myeloma
... Researchers have also developed a newer version of this drug called daratumumab hyaluronidase-fihj (Darzalex Faspro). Although daratumumab is typically given intravenously (through an IV infusion), daratumumab hyaluronidase-fihj treatments are simply injected under the skin (subcutaneously) and thus administered much faster. The U.S. ...
... One targeted therapy, daratumumab and hyaluronidase-fihj (Darzalex Faspro), is approved by the U.S. Food and Drug Administration (FDA) to treat both amyloidosis and myeloma. Other myeloma targeted therapies are not yet approved for amyloidosis, but doctors may recommend using them off-label to treat amyloidosis. ...
Amyloidosis: How Is It Different From Multiple Myeloma?
... One targeted therapy, daratumumab and hyaluronidase-fihj (Darzalex Faspro), is approved by the U.S. Food and Drug Administration (FDA) to treat both amyloidosis and myeloma. Other myeloma targeted therapies are not yet approved for amyloidosis, but doctors may recommend using them off-label to treat amyloidosis. ...
... These include: Daratumumab (Darzalex) Daratumumab and hyaluronidase-fihj (Darzalex Faspro) Elotuzumab (Empliciti) Isatuximab-irfc (Sarclisa) 5. Combination TherapiesThe U.S. ...
... The most common side effects are: Nausea Back pain Fever Cough Fatigue Low blood cell counts Daratumumab and Hyaluronidase-FihjThis form of daratumumab (Darzalex Faspro), which is combined with hyaluronidase-fihj, is given as a subcutaneous (under the skin) injection. ...
Myeloma Treatments: Risks and Benefits
... The most common side effects are: Nausea Back pain Fever Cough Fatigue Low blood cell counts Daratumumab and Hyaluronidase-FihjThis form of daratumumab (Darzalex Faspro), which is combined with hyaluronidase-fihj, is given as a subcutaneous (under the skin) injection. ...
... Food and Drug Administration (FDA) has approved multiple treatments, including the following: Daratumumab hyaluronidase-fihj (Darzalex Faspro) and isatuximab-irfc (Sarclisa) are monoclonal antibodies that recognize CD38, a protein on the surface of myeloma cells. These drugs help the immune system find and destroy those cells. ...
Relapsed vs. Refractory: What It Means in Multiple Myeloma
... Food and Drug Administration (FDA) has approved multiple treatments, including the following: Daratumumab hyaluronidase-fihj (Darzalex Faspro) and isatuximab-irfc (Sarclisa) are monoclonal antibodies that recognize CD38, a protein on the surface of myeloma cells. These drugs help the immune system find and destroy those cells. ...
... Once Darzalex binds to CD38 on the myeloma cell, it will attract immune cells known as natural killer cells to come and destroy the myeloma cell. Sarclisa Sarclisa (isatuximab-ifrc) works similarly to Darzalex. ...
Immunotherapy for Multiple Myeloma: What To Know
... Once Darzalex binds to CD38 on the myeloma cell, it will attract immune cells known as natural killer cells to come and destroy the myeloma cell. Sarclisa Sarclisa (isatuximab-ifrc) works similarly to Darzalex. ...
Join
